Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07202884) titled 'A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Urinary Incontinence,Stress
Intervention:
Drug: Orforglipron
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 2025
Target Sample Size: 1000
Countries of Recruitment:
United States
Canada
China
Czechia
India
Japan
Mexico...